



# Q1 2026 Financial Results and Business Updates

May 14, 2026

For Investor communication only. Not for use in product  
promotion. Not for further distribution.



[Autolus.com](https://www.autolus.com)

# Disclaimer

These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to: statements regarding Autolus’ development and commercialization of its product candidates; Autolus' manufacturing, sales and marketing plans for AUCATZYL, including expectations regarding the commercial launch in the United States and the ability to reach patients in a timely manner; the amount and timing of milestone payments under Autolus' collaboration and license agreements; and future development plans of obe-cel, including the timing or likelihood of expansion into additional markets or geographies and related regulatory approvals. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: Autolus' ability to maintain regulatory approval of AUCATZYL; its ability to execute its commercialization strategy for AUCATZYL; its ability to develop, manufacture and commercialize its other product candidates and the timing or likelihood of expansion of AUCATZYL into additional markets or geographies; Autolus' ability to maintain a commercial infrastructure and to successfully launch, market and sell AUCATZYL; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; the labelling for AUCATZYL/obe-cel in any future indication or patient population, if approved; the potential for payors to delay, limit or deny coverage for AUCATZYL; Autolus' ability to obtain, maintain and enforce intellectual property protection for AUCATZYL or any product candidates it is developing; the results of clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 27, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the presentation, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation.

# Agenda

- Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications
- Operational Highlights: Dr. Christian Itin, CEO
- Financial Results: Rob Dolski, CFO
- Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO
- Q&A: Dr. Christian Itin and Rob Dolski

# AUCATZYL® is gaining traction in US and UK markets

## AUCATZYL Global Net Product Revenue

Q1 2026: **\$26.2 million**



- Penetration into US market deepening with positive physician experience – as highlighted in recently reported ROCCA data & Autolus ALL investor event
- Early in UK launch, interest and awareness of AUCATZYL is high

## 2026 Expectations

FY 2026 Net Product Revenue:  
**\$120-\$135 million**

**Increase commercial footprint** in the US to more than 80 treatment centers and ongoing launch in the UK



Shift to **positive gross margin in 2026** based on increasing volumes and improved manufacturing plant operation

# Path to profitability in the ALL business

Optimizing the operating model and driving cost efficiency

## Cost reduction initiatives aimed at driving gross profit margin improvements

**Reduction in force** affecting approximately 13% of existing overall workforce


**Doubling manufacturing of products** for commercial and clinical trial patients in 2026

Actions expected to reduce operating expenses by approximately **\$15 million** on an annualized basis beginning in 2027 while product revenues are increasing

Peak: expect gross profit margin of 65-70%

Optimization: Improve efficiency and increase volumes to drive margins

Launch: Establish consistent and high-quality product supply and service



## Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL

Indication	Trial	Status
Pediatric r/r B-ALL	CATULUS Phase 1/2	Phase 2 expansion enrolling; data expected at end of 2027 Aligned with FDA on protocol design to support potential registration
Systemic Lupus (SLE)	CARLYSLE Phase 1	Initial data reported; longer-term follow up expected at end of 2026
Lupus Nephritis (LN)	LUMINA Phase 2	Phase 2 enrolling; data expected in 2028 Aligned with FDA on protocol design to support potential registration
Progressive Multiple Sclerosis	BOBCAT Phase 1	Phase 1 enrolling; initial data expected at end of 2026; full data in 2027

### Supported by external opportunities:

- Investigator-sponsored trials in earlier line settings of acute lymphoblastic leukemia (ALL)
- Real world experience obe-cel data being generated by ROCCA Consortium in r/r aALL

# Financial Results

## Financial summary – key metrics\*

USD (\$' 000)	Q1 2026	Q1 2025	Variance
<b>Product revenue, net</b>	<b>26,218</b>	<b>8,982</b>	<b>17,236</b>
<b>Cost and operating expenses:</b>			
Cost of sales	(24,568)	(17,951)	(6,617)
Research and development expenses, net	(21,210)	(26,734)	5,524
Selling, general and administrative expenses	(39,953)	(29,537)	(10,416)
<b>Loss from operations</b>	<b>(59,513)</b>	<b>(65,240)</b>	<b>5,727</b>
<b>Total comprehensive loss</b>	<b>(72,869)</b>	<b>(59,093)</b>	<b>(13,776)</b>

\*Select metrics only; for full financials please refer to the Company's 10-Q filing

**\$229.4M\*\***  
as of  
March 31,  
2026

Based on current operating plans, including anticipated AUCATZYL<sup>®</sup> net revenues, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company's operations into Q4 2027.

\*\*Cash, cash equivalents and marketable securities



Upcoming news flow

## Upcoming milestones

Anticipated Milestone or Catalyst	Anticipated Timing
Longer-term follow up data from CARLYSLE trial	Year End 2026
Initial clinical data from BOBCAT Phase 1 trial in progressive MS	Year End 2026
Initial clinical data from ALARIC Phase 1 trial in AL amyloidosis (UCL collab)	Year End 2026
BOBCAT trial Phase 1 full data	2027
CATULUS trial pediatric Phase 2 data	Year End 2027
LUMINA trial LN Phase 2 data	2028

Autolus

Thank you